Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its breakthrough approach, Fuse Vectors aims to be the universal solution for AAV ...

New gene therapy for maple syrup urine disease shows promise in preventing deadly symptoms in cows and offers hope for patients.

Looking forward, greater use of column chromatography technologies in vector manufacturing could facilitate the adoption of ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE ...

Researchers from the NIHR Moorfields Biomedical Research Centre and University College London have found that gene therapy improved visual acuity and preserved retinal structure in young children with ...